Bioclinica Acquires Saliency to Accelerate Digital Diagnostic Development

LG Thin-Clients Feature Built-in RFID Capabilities Optimized for Use in Healthcare Facilities

Supporting its mission to help healthcare providers streamline operations and deliver exceptional patient care, LG Business Solutions USA introduced a new LG thin client...

Experien Group Acquired by Veranex

Veranex combines product development, regulatory, and market access expertise — globally and across complex and emerging markets.

January 6, 2021

Bioclinica will integrate the company’s advanced AI technology into its Imaging Platform to support a growing portfolio of pharmaceutical and medical device clients.

The integration will dramatically accelerate image QC and interpretation, enabling rapid development of digital diagnostics and digital therapeutics.

“Clients rely on us for time-sensitive expert-level image interpretation for their clinical trials so they can focus on outcomes,” said Dan Gebow, PhD, Chief Innovation Officer at Bioclinica. “We evaluated a variety of medical imaging AI platforms and know the Saliency platform is head and shoulders above others in the market in its ability to deliver value for our clients.”

The Saliency platform uses proprietary algorithms to quickly build and train AI models from a small number of de-identified images. These newly created models can then be used to accurately and efficiently screen, redact, or interpret medical images to support a wide range of therapeutic areas. This capability will be embedded into Bioclinica’s current and future imaging solutions in accordance with EU GDPR and other privacy regulations.

“This integration empowers industry stakeholders with the absolute latest in medical imaging technology by delivering custom AI models faster and with more accuracy,” said Kevin Thomas, MD/PhD, CEO of Saliency. “We are proud to combine our state-of-the-art cloud-based tools with Bioclinica’s unrivaled imaging expertise,” added Łukasz Kidziński, PhD, Saliency’s President and CTO.

The Saliency acquisition solidifies Bioclinica’s position as the premier global provider of research image technology and services to sponsors and Clinical Research Organizations. The AI integration will create a perpetual learning system that will enable Bioclinica to expand its portfolio and drive new revenue with its enhanced offering.

Saliency’s co-founders, Kevin Thomas, MD/PhD, candidate at Stanford University School of Medicine and Łukasz Kidziński, PhD, formerly of Stanford’s Bioengineering & Statistics, will join Bioclinica’s Image Science team, further strengthening the company’s medical imaging expertise and offerings.

spot_img

DON'T MISS

Graham Belgrave Named to the 2021 PharmaVOICE 100 List of Distinguished Leaders

At Advanced Clinical, and from previous organizations, Belgrave serves as a mentor to several colleagues, where he challenges them to think outside of the box and take risks.

Mediclinic Appoints 2 New Independent Non-Executive Directors

Natalia Barsegiyan and Zarina Bassa will bring significant and diverse skills and experience, complementing those of existing Board members. I am confident they will both be great additions to our Board of Directors.”

Our Sister Publication: Biotechnology News Magazine

Subscribe to Medical Device News Magazine here.